Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05422053 · ClinicalTrials.gov registry record · NA
Control-IQ Technology for High Insulin Users With Type 1 Diabetes (Higher-IQ)
A NA study, sponsored by Tandem Diabetes Care.
- Completed
- Registry status
- NA
- Development phase
- 34
- Enrollment target
NCT05422053 is a NA study that has completed, run by Tandem Diabetes Care. The registered enrollment target is 34 participants.
The verdict
NCT05422053, a NA study, has completed, sponsored by Tandem Diabetes Care.
- COMPLETED
- Registry status
- NA
- Development phase
- 34 participants
- Enrollment target
Study Summary
A prospective, single-arm study of 13 weeks of home use of the t:slim X2 insulin pump with Control-IQ technology in individuals with type 1 diabetes who will plan to use at least one basal rate \> 3 units/hr.
Interventions
- DEVICE t:slim X2 insulin pump with Control-IQ technology 1.5
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 2022-06-29 |
| Est. Completion | 2023-01-06 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05422053
The ClinicalTrials.gov registry entry for NCT05422053 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 34 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Tandem Diabetes Care, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which t:slim X2 insulin pump with Control-IQ technology 1.5 is the first listed.
NCT05422053 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05422053 about?
NCT05422053 is a clinical study titled "Control-IQ Technology for High Insulin Users With Type 1 Diabetes (Higher-IQ)". A prospective, single-arm study of 13 weeks of home use of the t:slim X2 insulin pump with Control-IQ technology in individuals with type 1 diabetes who will plan to use at least one basal rate \> 3 units/hr.
What is the current status of trial NCT05422053?
This trial is currently completed. It is a NA study. The enrollment target is 34 participants. The study started on 2022-06-29. Estimated completion is 2023-01-06.
What interventions are being tested in trial NCT05422053?
The interventions under investigation include: t:slim X2 insulin pump with Control-IQ technology 1.5 (DEVICE).
Who is sponsoring clinical trial NCT05422053?
This trial is sponsored by Tandem Diabetes Care, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.